Year: 2025
Type: editorial
Abstract: understand the mechanisms regulating development and disease progression (2)(3)(4). The contributions assembled in this Research Topic reflect the innovation in this space, offering not only therapeutic hope but also new conceptual frameworks for understanding kidney regeneration and disease mechanisms.The emerging idea that the adult kidney may regain regenerative abilities through transcriptional reprogramming is at the base of the study by Pode-Shakked and colleagues. This study explores the reactivation of developmental genes, SIX2 and OSR1, in adult human kidney epithelial cells, demonstrating how developmental biology can be exploited to induce regenerative processes. By reintroducing SIX2, the Authors observed an enhancement in cellular self-renewal and in the ability to form organized tubular structures in vivo, suggesting that adult kidney cells retain plasticity that can be unlocked when cells are stimulated by specific signaling. Yet, the study also serves as a cautionary tale: OSR1, while activating developmental programs, was associated with malignant transformation in a subset of cells, mimicking features of Wilms tumor. This duality of regeneration versus tumorigenesis underscores the fragile balance that must be maintained when manipulating developmental pathways in adult tissues.Complementary, the work by Gyarmati et al. shifts attention to an often-overlooked player in renal physiology: the macula densa. Traditionally viewed as a sensor of tubular sodium concentration, the macula densa is revealed here as a potent source of regenerative signals. The identification of CCN1, an angiogenic and anti-fibrotic factor, positions the macula densa as a novel therapeutic target and a potential cellular source for regenerative interventions. This discovery frames the macula densa cells as a regenerative niche, underscoring their relevance in the field by leveraging the kidney's intrinsic repair mechanisms rather than relying solely on exogenous cell replacement.While cellular therapies hold great promise, the challenges of immunogenicity, scalability, and safety have prompted interest in cell-free alternatives. The review by Ceccotti and colleagues offers a comprehensive and timely synthesis of the therapeutic potential of mesenchymal stem cell-derived extracellular vesicles (MSC-EVs). These vesicles, enriched with specific regenerative cargo, have demonstrated the ability to modulate inflammation, fibrosis, and oxidative stress. The EV-based approach is particularly attractive due to its versatility and safety profile. By combining the therapeutic effects of stem cells into a nano-sized, acellular format, MSC-EVs circumvent many of the regulatory hurdles associated with live cell therapies. The review not only consolidates the preclinical evidence but also points to early clinical data suggesting feasibility and safety, paving the way for broader EV translational efforts for kidney disease. Looking ahead, several hurdles will need to be addressed. First, the field must continue to refine strategies that balance efficacy with safety, particularly when manipulating potent developmental genes. Second, there is a need for more physiologically relevant models that can bridge the gap between preclinical promise and clinical application. Third, standardization of cell sources, EV isolation protocols, and delivery methods will be critical for regulatory approval and widespread adoption. Finally, the integration of personalized medicine approaches, including patient-derived cells and organoids, will be essential to tailor therapies to individual disease profiles and genetic backgrounds.In sum, the contributions in this Research Topic, while presenting recent discoveries related to kidney regeneration, redefine its possibilities. These studies offer us a glimpse into a future where kidney failure will be a treatable condition, where regeneration replaces replacement, and where the kidney's own biology becomes its best medicine.
Language: English
Topic: Renal and related cancers
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W4416775864